| P2093 | author name string | Malcolm J Whiting | |
| | Matthew P Doogue | |
| P2860 | cites work | Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma | Q73082442 |
| | Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma | Q73102614 |
| | Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients | Q73129936 |
| | Incidentally discovered adrenal tumors: endocrine and scintigraphic correlates | Q74065141 |
| | Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan | Q79251440 |
| | Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients | Q79354820 |
| | Stability of urinary fractionated metanephrines and catecholamines during collection, shipment, and storage of samples | Q79421893 |
| | Reboxetine treatment and pseudopheochromocytoma | Q79439160 |
| | Is supine rest necessary before blood sampling for plasma metanephrines? | Q79475892 |
| | Chromatographic behaviour and comparison of column packed with sub-2 microm stationary phases in liquid chromatography | Q79920846 |
| | The role of chromogranin A in the management of patients with phaeochromocytoma | Q80138400 |
| | An analysis of the biochemical diagnosis of 66 pheochromocytomas | Q80236441 |
| | Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy | Q80562953 |
| | Another cause of 'pseudophaeochromocytoma'--quetiapine associated with a false positive normetanephrine result | Q80654181 |
| | Chromogranin A, a member of neuroendocrine secretory proteins as a selective marker for laboratory diagnosis of pheochromocytoma | Q80691849 |
| | High-throughput, automated, and accurate biochemical screening for pheochromocytoma: are we there yet? | Q80825422 |
| | Plasma free metanephrine measurement using automated online solid-phase extraction HPLC tandem mass spectrometry | Q80825436 |
| | Pheochromocytoma | Q94037585 |
| | Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine | Q22242284 |
| | Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 |
| | A systematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of pheochromocytoma | Q24804448 |
| | Tetrahydropterin-dependent amino acid hydroxylases | Q28139425 |
| | Liquid Chromatography–Tandem Mass Spectrometry Method for the Determination of Vanillylmandelic Acid in Urine | Q28199104 |
| | TYROSINE HYDROXYLASE. THE INITIAL STEP IN NOREPINEPHRINE BIOSYNTHESIS | Q28201039 |
| | Biochemical diagnosis of pheochromocytoma: which test is best? | Q28208107 |
| | Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations | Q28278673 |
| | Effects of Bromocriptine on Plasma Catecholamines in Normal Men | Q28327333 |
| | A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours | Q28359544 |
| | Drug Points: Pseudophaeochromocytoma syndrome associated with clozapine | Q28365317 |
| | Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma | Q33430861 |
| | von Recklinghausen's disease and pheochromocytomas | Q33753382 |
| | British Hypertension Society guidelines for hypertension management 1999: summary | Q33797387 |
| | Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results | Q34203293 |
| | Understanding catecholamine metabolism as a guide to the biochemical diagnosis of pheochromocytoma | Q34438830 |
| | Pheochromocytomas: can malignant potential be predicted? | Q34502999 |
| | Germ-line mutations in nonsyndromic pheochromocytoma | Q34523021 |
| | Malignant pheochromocytoma: current status and initiatives for future progress | Q34550903 |
| | New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholamines | Q34967592 |
| | The management of benign and malignant pheochromocytoma and abdominal paraganglioma | Q35092215 |
| | Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience | Q35558884 |
| | Measurement of catecholamines and their metabolites | Q35624577 |
| | The clinically inapparent adrenal mass: update in diagnosis and management | Q35745002 |
| | The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls | Q36182070 |
| | Phaeochromocytoma | Q36236107 |
| | Adrenal incidentalomas -- a continuing management dilemma | Q36261442 |
| | Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data | Q36480428 |
| | An overview of pheochromocytoma: history, current concepts, vagaries, and diagnostic challenges | Q36652761 |
| | Genetic testing in pheochromocytoma: increasing importance for clinical decision making | Q36652769 |
| | Clinical review: Current treatment of malignant pheochromocytoma | Q36729834 |
| | Molecular and cellular biology of pheochromocytomas and extra-adrenal paragangliomas | Q36831552 |
| | Evidence of MEN-2 in the original description of classic pheochromocytoma. | Q36952963 |
| | Prediction of human pharmacokinetics - renal metabolic and excretion clearance | Q36988426 |
| | Pheochromocytoma: an update on genetics and management | Q37018391 |
| | Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. | Q37023863 |
| | Measurement of urinary metanephrines to screen for pheochromocytoma in an unselected hospital referral population | Q37093122 |
| | A decade of HPLC-MS/MS in the routine clinical laboratory--goals for further developments | Q37122300 |
| | Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma | Q37311127 |
| | Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma | Q37367793 |
| | Current concepts. Pheochromocytoma: diagnosis, localization and management | Q40095614 |
| | Prevalence of clinically unsuspected pheochromocytoma. Review of a 50-year autopsy series | Q40218381 |
| | Binding and clearance of radioactive adrenaline and noradrenaline in sheep blood. | Q40347975 |
| | Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocytoma: diagnostic value in 19 cases. | Q40621025 |
| | Hormone storage vesicle proteins. Transcriptional basis of the widespread neuroendocrine expression of chromogranin A, and evidence of its diverse biological actions, intracellular and extracellular | Q40642502 |
| | Clinical experience over 48 years with pheochromocytoma | Q40810053 |
| | Epinephrine and norepinephrine responses in continuously collected human plasma to a series of stressors | Q41590285 |
| | Pseudopheochromocytoma and cardiac arrest associated with phenylpropanolamine | Q42225703 |
| | Pheochromocytoma in Italy: a multicentric retrospective study | Q42481322 |
| | Determination of homovanillic acid in urine by stable isotope dilution and electrospray tandem mass spectrometry | Q43561992 |
| | Free or total metanephrines for diagnosis of pheochromocytoma: what is the difference? | Q43618846 |
| | 47 years of phaeochromocytomas | Q43788150 |
| | Evaluation of specific high-performance liquid-chromatographic determinations of urinary metanephrine and normetanephrine by comparison with isotope dilution mass spectrometry | Q43815141 |
| | Analysis of catecholamines in urine by positive-ion electrospray tandem mass spectrometry | Q43862826 |
| | Validation of liquid chromatography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. | Q43893214 |
| | Extraction and separation of urinary catecholamines as their diphenyl boronate complexes using C18 solid-phase extraction sorbent and high-performance liquid chromatography | Q43983681 |
| | Adrenal incidentaloma--experience of a standardized diagnostic programme in the Swedish prospective study | Q44148281 |
| | A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines | Q44306785 |
| | The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. | Q44393465 |
| | Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. | Q44590672 |
| | Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan | Q44840812 |
| | The economic implications of three biochemical screening algorithms for pheochromocytoma | Q44924343 |
| | Paracetamol-associated interference in an HPLC-ECD assay for urinary free metadrenalines and catecholamines | Q45010024 |
| | Simultaneous measurement of urinary metanephrines and catecholamines by liquid chromatography with tandem mass spectrometric detection | Q46142317 |
| | Clinical characteristics of pheochromocytoma patients with germline mutations in SDHD. | Q46387529 |
| | Isopropanol protein precipitation for the analysis of plasma free metanephrines by liquid chromatography-tandem mass spectrometry | Q46440186 |
| | Biochemical detection of phaeochromocytoma: why are we continuing to ignore the evidence? | Q46753276 |
| | Genetic testing in pheochromocytoma or functional paraganglioma | Q46825172 |
| | Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. | Q46827190 |
| | Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass | Q46960655 |
| | A simple, optimised and rapid assay for urinary free catecholamines by HPLC with electrochemical detection | Q49215963 |
| | Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. | Q50952441 |
| | Sources and physiological significance of plasma dopamine sulfate. | Q51562363 |
| | Phaeochromocytoma, new genes and screening strategies. | Q51928317 |
| | Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? | Q51928842 |
| | Plasma adrenaline, noradrenaline and dopamine in man and different animal species | Q52965432 |
| | The diagnostic efficacy of urinary fractionated metanephrines measured by tandem mass spectrometry in detection of pheochromocytoma. | Q53492078 |
| | Adrenal incidentaloma - follow-up results from a Swedish prospective study. | Q53550245 |
| | Pseudopheochromocytoma After Self-administered Isoproterenol | Q54631233 |
| | Renal Tubular Drug Transporters | Q60019038 |
| | Simple and fast solvent extraction system for selective and quantitative isolation of adrenaline, noradrenaline and dopamine from plasma and urine | Q63352184 |
| | The binding of catecholamines to human serum proteins | Q66921294 |
| | Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications | Q66930405 |
| | Improved solid-phase extraction and liquid chromatography with electrochemical detection of urinary catecholamines and 5-S-L-cysteinyl-L-dopa | Q67248528 |
| | Urinary catecholamine assay by HPLC: in vitro interference by some drugs | Q68044743 |
| | Urinary Normetanephrine and Metanephrine Measured by Radioimmunoassay for the Diagnosis of Pheochromocytoma: Utility of 24-Hour and Random 1-Hour Urine Determinations | Q68488684 |
| | Plasma and urinary catecholamines as related to renal function in man | Q68968548 |
| | Renal handling of norepinephrine and epinephrine in the pig | Q69970706 |
| | Preparation of urine samples for liquid-chromatographic determination of catecholamines: bonded-phase phenylboronic acid, cation-exchange resin, and alumina adsorbents compared | Q70049215 |
| | Determination of catecholamines in urine (and plasma) by liquid chromatography after on-line sample pretreatment on small alumina or dihydroxyborylsilica columns | Q70175527 |
| | Determination of metanephrines in plasma by liquid chromatography with electrochemical detection | Q70526789 |
| | Incidentally discovered adrenal masses | Q70787813 |
| | Differential assay for urinary catecholamines by use of liquid chromatography with fluorescence detection | Q70790814 |
| | Simultaneous determination of catecholamines and metanephrines in urine by HPLC with fluorometric detection | Q71294579 |
| | Regional release and removal of catecholamines and extraneuronal metabolism to metanephrines | Q71744029 |
| | Evaluation of urinary metanephrine and normetanephrine enzyme immunoassay (ELISA) kits by comparison with isotope dilution mass spectrometry | Q71960684 |
| | Plasma metanephrines in the diagnosis of pheochromocytoma | Q72307135 |
| P433 | issue | 1 | |
| P304 | page(s) | 3-17 | |
| P577 | publication date | 2009-02-01 | |
| P1433 | published in | Clinical Biochemist Reviews | Q15766391 |
| P1476 | title | Advances in biochemical screening for phaeochromocytoma using biogenic amines | |
| P478 | volume | 30 | |